• Jibu

  Participated · Series B · Feb 2018

  Jibu operates a franchise network that enables local entrepreneurs to deliver safe drinking water and related services in emerging-market communities. The company scaled from two franchises in two countries in 2015 to more than 200 businesses in Kenya, Uganda and Rwanda. It has adapted a licensing model in Zimbabwe to partner with a local investor-entrepreneur with plans to grow to more than 90 franchises there, and is piloting the model in Tanzania. Jibu is led by co-founders Randy Welsch (Co-Founder and President) and Galen Welsch (Co-Founder and Chief Executive Officer). The company will use the Series B proceeds to accelerate a planned launch of 1,000 drinking water franchises in at least a dozen new countries by 2022. After the $7M Series B, Jibu has raised more than $10M in total.

• Advanced Catheter Therapies

  Participated · Series A · Sep 2011

  Advanced Catheter Therapies (ACT) is a Chattanooga, TN-based research and development medical device company with a portfolio of innovative catheter technologies addressing vascular disease and targeted endovascular drug delivery. Led by CEO Paul J. Fitzpatrick, the company’s lead product is the Occlusion Perfusion Catheter™ (OPC), a multi‑lumen balloon catheter designed to temporarily occlude a specific region to allow targeted delivery of therapeutic and diagnostic agents to the peripheral vasculature. The OPC is disease- and agent-agnostic, can create a localized treatment chamber and place agent circumferentially into the vasculature, and includes inflow and outflow ports for chamber evacuation, filling and flushing. ACT recently received the first limited shipment of the OPC. The device is patented and 510(k) cleared. The company intends to use new funding to bring the OPC to market for targeted applications. Advanced Catheter Therapies develops innovative catheter technologies with an initial focus on vascular disease conditions such as thrombosis, inflammation, occlusions and restenosis. The company’s pipeline centers on the patented Occlusion Perfusion Catheter (OPC), an intravascular agent delivery device. ACT has filed for 510(k) FDA approval for the OPC and is pursuing commercialization or out‑licensing of the technology. The firm is led by CEO Paul J. Fitzpatrick and operates from Chattanooga, Tennessee. The recent financing will fund further device development across ACT’s product pipeline. No operating metrics (revenue/users) were disclosed in the article. Atlanta Catheter Therapies develops a portfolio of catheter technologies aimed at treating vascular disease and preventing restenosis. Its lead product is the Occlusion Perfusion Catheter™ (OPC), an intravascular agent delivery device. The company intends to use new funds to advance and commercialize the OPC and to develop other technologies in its pipeline. It also plans to use proceeds for working capital and general corporate purposes. Atlanta Catheter Therapies is led by CEO Paul J. Fitzpatrick and was founded in 2008 by Dr. Rex Teeslink. The company is based in Chattanooga, TN.

No current team members are available.